Experimental transmission of SIV to Asian macaque monkeys (rhesus) of, induces a fatal immunodeficiency disease which resembles AIDS in humans infected with HIV-1 or HIV-2. Thus, SIV infection of rhesus macaques offers a highly manipulatable animal lentivirus system that can be used to analyze pathogenesis and to test and develop strategies that inhibit virus replication and prevent disease. We will pursue the hypothesis that the SIV animal model can be used to elucidate principles that will guide testing and development of safe and effective anti-HIV vaccines.
SPECIFIC AIM 1 : Immunologic correlates of protective immunity will be identified. Comparative studies of immune responses of rhesus macaques infected with molecularly cloned SIVmac and uncloned SIVmac will be pursued to determine if differences in the clinical outcome of infection can be accounted for by the host immune response. These investigations will also examine effects of viral sequence variation on immune responses.
SPECIFIC AIM 2. Functional and immunological domains of the SIV envelope glycoprotein will be defined by characterizing envelope gene variants generated by site-directed mutagenesis.
SPECIFIC AIM 3. Vaccinia viruses expressing envelope genes of selected SIV variants and lymphokines, will be tested in rhesus macaques for induction of anti-viral immune responses and for protection against challenge with virulent SIV.
SPECIFIC AIM 4. Recombinant SIV antigens, produced in genetically engineered yeast and mammalian cells, will be evaluated with respect to immune responses and resistance to challenge.
SPECIFIC AIM 5. Macaques immunized with candidate SIV mac vaccines will be challenged by exposure of genital mucosa to a minimal infectious dose of cell-associated virus and cell-free virus. Results from specific Aids 1 and 2 on host immune responses and SIV strain variation will be relevant both for vaccine development and for understanding pathogenesis. The vaccinia vector systems in together with recombinant SIV antigens will be used to focus on immune responses to individual viral proteins; these materials will be essential for elucidating immune responses that may correlate with protective immunity. Additional important objectives in this proposal include standardization of assay for measuring anti-viral immune responses and for monitoring virus (i.e., detection of viral nucleic acid by polymerase chain reaction amplification). The research in this proposal may establish a procedure to achieve protective immunity in a non-human primate model against an immunosuppressive lentivirus. These results may be applicable for developing vaccination procedures to protect humans against HIV-1 infection and disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI029207-03
Application #
3547571
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Project Start
1989-09-30
Project End
1994-07-31
Budget Start
1991-08-01
Budget End
1992-07-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Veterinary Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Verardi, P H; Jones, L A; Aziz, F H et al. (2001) Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol 75:11-8
Jones, L; Ahmad, S; Chan, K et al. (2000) Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines. J Med Primatol 29:231-9
Giavedoni, L; Ahmad, S; Jones, L et al. (1997) Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol 71:866-72
Ahmad, S; Lohman, B; Marthas, M et al. (1994) Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses 10:195-204
Giavedoni, L D; Planelles, V; Haigwood, N L et al. (1993) Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 67:577-83
Haigwood, N L; Misher, L; Chin, S M et al. (1992) Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. J Med Primatol 21:82-90
Giavedoni, L D; Jones, L; Gardner, M B et al. (1992) Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A 89:3409-13
Lohman, B L; Higgins, J; Marthas, M L et al. (1991) Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol 29:2187-92